SGT-001 Safety and Efficacy Data Available from IGNITE DMD Clinical Trial
source: pixabay.com

SGT-001 Safety and Efficacy Data Available from IGNITE DMD Clinical Trial

Since its inception, life sciences company Solid Biosciences Inc. has been working to develop treatment options for patients with Duchenne muscular dystrophy (DMD). According to a recent press release, the…

Continue Reading SGT-001 Safety and Efficacy Data Available from IGNITE DMD Clinical Trial
This Phase 3 Study Will Evaluate Pamrevlumab as a Treatment for DMD
mohamed_hassan / Pixabay

This Phase 3 Study Will Evaluate Pamrevlumab as a Treatment for DMD

Pamrevlumab is a first-in-class antibody that treats Duchenne muscular dystrophy (DMD) by inhibiting the effects and activity of connective tissue disorder growth factor (CTGF). It is being developed by FibroGen,…

Continue Reading This Phase 3 Study Will Evaluate Pamrevlumab as a Treatment for DMD

Updates Available on Givinostat Clinical Development for DMD

During the virtual XVIII International Conference on Duchenne and Becker Muscular Dystrophy, specialty pharmaceutical company Italfarmaco Group ("Italfarmaco") shared updates regarding various Givinostat clinical development programs. The treatment is designed…

Continue Reading Updates Available on Givinostat Clinical Development for DMD
Love, Work, Progress, and Community in Facioscapulohumeral Muscular Dystrophy
source: pixabay.com

Love, Work, Progress, and Community in Facioscapulohumeral Muscular Dystrophy

Colette Wheeler is one of four siblings, and although each had only a 50/50 chance of inheriting the genetic mutation that leads to facioscapulohumeral muscular dystrophy (FSHD), all of them…

Continue Reading Love, Work, Progress, and Community in Facioscapulohumeral Muscular Dystrophy

Duchenne Muscular Dystrophy Trial has Gotten the Go Ahead from the FDA to Continue Dosing

Solid Biosciences has just reported that the FDA has finally lifted the hold they had placed on their Phase I/II trial for Duchenne muscular dystrophy (DMD). This trial is called…

Continue Reading Duchenne Muscular Dystrophy Trial has Gotten the Go Ahead from the FDA to Continue Dosing
Ataluren Halts Disease Progression in Patients with nmDMD
HeungSoon / Pixabay

Ataluren Halts Disease Progression in Patients with nmDMD

This year, at the 2020 CNS-ICNA Conjoint Meeting, researchers identified ataluren as a potential treatment that inhibits disease progression for patients with nonsense mutation Duchenne muscular dystrophy (nmDMD). Research suggests…

Continue Reading Ataluren Halts Disease Progression in Patients with nmDMD
Kevin Hart Gives a Hand to the Muscular Dystrophy Association As Host of the MDA Telethon
source: pixabay.com

Kevin Hart Gives a Hand to the Muscular Dystrophy Association As Host of the MDA Telethon

As sourced from BioSpace: After 44 years of the legendary Jerry Lewis hosting the Jerry Lewis MDA Telethon to bring awareness to this disorder, his tradition will live on in…

Continue Reading Kevin Hart Gives a Hand to the Muscular Dystrophy Association As Host of the MDA Telethon

CureDuchenne Webinar: Italfarmaco Givinostat Program Update

  • Post author:
  • Post category:

CureDuchenne Webinar: Update on the Italfarmaco Givinostat Program September 24, 2020 Hear from Dr. Paolo Bettica about the latest news related to Italfarmaco's investigational therapy givinostat, which is being tested…

Continue Reading CureDuchenne Webinar: Italfarmaco Givinostat Program Update
MRFF Funding Promotes Treatment Development for Patients with Rare Diseases
https://pixabay.com/en/money-piggy-bank-coins-finance-2180338/

MRFF Funding Promotes Treatment Development for Patients with Rare Diseases

  When it comes to researching and finding treatments for rare diseases, funding plays a crucial role. Recently, the Medical Research Future Fund (MRFF) Stem Cell Therapies Mission presented Monash…

Continue Reading MRFF Funding Promotes Treatment Development for Patients with Rare Diseases